InsiderPulseNo transactions found.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development | $1.8M-42.0% | $3.2M-36.2% | $5.0M-23.7% | $6.6M |
| Sales and marketing | $189K-66.8% | $571K-30.4% | $821K-42.6% | $1.4M |
| General and administrative | $3.7M-47.2% | $7.1M+50.2% | $4.7M-9.2% | $5.2M |
| Total operating expenses | $5.8M-46.7% | $10.8M+2.8% | $10.5M-20.0% | $13.2M |
| Operating loss | -$5.8M+46.7% | -$10.8M-2.8% | -$10.5M+20.0% | -$13.2M |
| Other income | $71K-34.3% | $108K-76.4% | $460K | — |
| Digital asset staking compensation | $5K | — | — | — |
| Change in fair value of digital assets | -$995K | — | — | — |
| Warrant expense | -$665K+90.9% | -$7.3M | — | — |
| Changes in fair value of warrant liability | $320K-90.7% | $3.4M | — | — |
| Gain on settlement of warrant exercise | $3.1M | — | — | — |
| Total other expenses | -$1.3M-83.0% | -$691K-250.0% | $460K+2238.5% | -$22K |
| Loss from operations before income taxes | -$7.0M+38.9% | -$11.5M-14.4% | -$10.1M+23.7% | -$13.2M |
| Provision for income taxes | — | — | $0 | $0 |
| Net Loss | -$7.0M+38.9% | -$11.5M-14.4% | -$10.1M+23.7% | -$13.2M |
| Net loss per share – basic (in Dollars per share) | -$8.93+84.3% | -$56.94 | — | — |
| Net loss per share – diluted (in Dollars per share) | -$8.93+84.3% | -$56.94+97.9% | -$3K | — |
| Weighted average common shares – basic (in Shares) | $787K+289.4% | $202K | — | — |
| Weighted average common shares – diluted (in Shares) | $787K+289.4% | $202K+5458.5% | $4K | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility
Endra Life Sciences GAAP EPS of -$8.93 misses by $2.34
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update